EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Is there a biochemical basis for purinergic P2X3 and P2X4 receptor antagonists to be considered as anti-seizure medications?

Jeffrey M Witkin, Hana Shafique, Jodi L Smith, Rok Cerne

Biochemical Pharmacology · 2024

DOI: 10.1016/j.bcp.2024.116046 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Jeffrey M Witkin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, Indianapolis, IN, USA; Department of Neuroscience and Trauma Research, Ascension S…. Hauptthemen laut MEDLINE: Purinergic P2X Receptor Antagonists, Epilepsy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with epilepsy require improved medications. Purinergic receptors were identified as late as 1976 and are slowly emerging as potential drug targets for the discovery of antiseizure medications. While compounds interacting with these receptors have been approved for use as medicines (e.g., gefapixant for cough) and continue to be explored for a number of diseases (e.g., pain, cancer), there have been no purinergic receptor antagonists that have been advanced for epilepsy. There are very few studies on the channel conducting receptors, P2X3 and P2X4, that suggest their possible role in seizure generation or control. However, the limited data available provides some compelling reasons to believe that they could be valuable antiseizure medication drug targets. The data implicating P2X3 and P2X4 receptors in epilepsy includes the role played by ATP in neuronal excitability and seizures, receptor localization, increased receptor expression in epileptic brain, the involvement of these receptors in seizure-associated inflammation, crosstalk between these purinergic receptors and neuronal processes involved in seizures (GABAergic and glutamatergic neurotransmission), and the significant attenuation of seizures and seizure-like activity with P2X receptor blockade. The discovery of new and selective antagonists for P2X3 and P2X4 receptors is ongoing, armed with new structural data to guide rational design. The availability of safe, brain-penetrant compounds will likely encourage the clinical exploration of epilepsy as a disease entity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purinergic P2X Receptor AntagonistsEpilepsyHumansPainReceptors, Purinergic P2X4SeizuresReceptors, Purinergic P2X3Adenosine Triphosphate

Stichwörter der Autor:innen

AnticonvulsantDrug discoveryEpilepsyP2X3 receptorsP2X4 receptors

Substanzen

Purinergic P2X Receptor AntagonistsReceptors, Purinergic P2X4Receptors, Purinergic P2X3Adenosine Triphosphate

Autor:innen und Institutionen

  • Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, Indianapolis, IN, USA; Department of Neuroscience and Trauma Research, Ascension St. Vincent, Indianapolis, IN, USA; Department of Chemistry & Biochemis…
  • Duke University School of Medicine, Durham, NC, USA.
  • Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, Indianapolis, IN, USA.
  • Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, Indianapolis, IN, USA; Department of Anatomy and Cell Biology, Indiana University/Purdue University, Indianapolis, IN, USA; Faculty of Medicine, Univers…

Zitieren

APA

Witkin, J. M., Shafique, H., Smith, J. L., & Cerne, R. (2024). Is there a biochemical basis for purinergic P2X3 and P2X4 receptor antagonists to be considered as anti-seizure medications?. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116046

Vancouver

Witkin JM, Shafique H, Smith JL, Cerne R. Is there a biochemical basis for purinergic P2X3 and P2X4 receptor antagonists to be considered as anti-seizure medications?. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116046

BibTeX
@article{Witkin2024,
  author = {Witkin, Jeffrey M and Shafique, Hana and Smith, Jodi L and Cerne, Rok},
  title = {Is there a biochemical basis for purinergic P2X3 and P2X4 receptor antagonists to be considered as anti-seizure medications?},
  journal = {Biochemical Pharmacology},
  year = {2024},
  doi = {10.1016/j.bcp.2024.116046}
}
Kostenlos starten →